PM
HRTX icon

Parametrica Management’s Heron Therapeutics HRTX Stock Holding History

Parametrica Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11,010
Closed -$129K – 195
2020
Q1 		$129K Buy
+11,010
New +$207K 0.13% 202

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Parametrica Management's HRTX Position: Q2 2020 in Review

Parametrica Management sold out of Heron Therapeutics (HRTX) in Q2 2020, closing a stake of 11,010 shares — an estimated $129K sold.

Parametrica Management first reported a position in HRTX in Q1 2020 and held it in 1 quarter. The position peaked at $129K in Q1 2020. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2020.

  • Parametrica Management reported no remaining Heron Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Parametrica Management sold 11,010 Heron Therapeutics shares in Q2 2020, an estimated $129K.
  • Parametrica Management first reported a position in Heron Therapeutics in Q1 2020 and held it in 1 quarter.
  • Parametrica Management's Heron Therapeutics position peaked at $129K in Q1 2020.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2020.

Based on Parametrica Management's 13F filing for Q2 2020, filed 17 Aug 2020.